Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients

European Journal of Clinical Pharmacology

Volumn 60, Issue 12, 2005, Pages 843-848

  Wang, An ^a   Yu, Bang Ning ^a   Luo, Chen Hui ^a   Tan, Zhi Rong ^a   Zhou, Gan ^a   Wang, Lian Sheng ^a   Zhang, Wei ^a   Li, Zhi ^a   Liu, Jie ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXYHYDROCORTISONE; ACETYLSALICYLIC ACID; ALPRENOLOL; AMPICILLIN; ANTILIPEMIC AGENT; CAPTOPRIL; CHOLESTEROL; CYTOCHROME P450 3A4; FELODIPINE; HYDROCORTISONE; ISOLEUCINE; LIPID; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VALINE;

ADULT; AGED; ANALYZER; ARTICLE; AUTOMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TANDEM MASS SPECTROMETRY; URINE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHOLESTEROL; CORTISONE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; HUMANS; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; ISOLEUCINE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SIMVASTATIN; TRIGLYCERIDES; VALINE;

EID: 20144378997     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0848-7     Document Type: Article

References (32)

1. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992) Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878
2. Boxenbaum H (1999) Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 2:47-52
3. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17
4. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ (2001) CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metab Dispos 29:133-140
5. Wang RW, Newton DJ, Scheri TD, Lu AY (1997) Human cytochrome P450 3A4-catalyzed testosterone 6 beta- hydroxylation and erythromycin N-demethylation. Competition during catalysis. Drug Metab Dispos 25:502-507
6. Ozdemir V, Kalow W, Tang B-K, Paterson AD, Walker SE, Endrenyi L et al (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388
7. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5′- promoter region of CYP3A4. Clin Pharmacol Ther 66:288-294
8. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229
9. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56
10. Kun-Pin H, Yen-Yu L, Ching-Ling C, Ming-Liang L, Min-Shung L, Jean-Pascal S, Jin-Ding H (2001) Novel Mutations of CYP3A4 in Chinese. Drug Metab Dispos 29(3):268-273
11. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan- Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, Khan KK, He YA, Halpert JR, Wojnow-ski L (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458
12. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132
13. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831
14. Prueksaritanont T, Gorham LM, Ma B et al (1997) In vitro metabolism of simvastatin in humans: identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 25:1191-1199
15. Vickers S, Duncan CA, Chen I-W, Rosegay A, Duggan DE (1990) Metabolic disposition studies of simvastatin, a cholesterollowering prodrug. Drug Metab Dispos 18:138-145
16. Transon C, Leeman T, Dayer P (1996) In vitro comparative inhibition profiles of major drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 50:209-215
17. Mulder AB, van Lijf HJ, Bon MA, van den Bergh FA, Touw DJ, Neef C, et al (2001) Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 70:546-551
18. Nordin C, Dahl ML, Eriksson M, Sjoberg S (1997) Is the cholesterollowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet 350:29-30
19. Geisel J, Kivistö KT, Griese EU, Eichelbaum M (2002) The efficacy of simvastatin is not influenced by CYP2D6 polymorphism. Clin Pharmacol Ther 72(5):595-596
20. Prueksaritanont T, Ma B, Yu N (2003) The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. Br J Clin Pharmacol 56:120-124
21. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory manual, 2nd edn.Cold Spring Harbor Laboratory, Cold Spring Harbor, pp16-19
22. Taylor RL, Machacek D, Singh RJ (2002) Validation of a high-throughput liquid chromatography-tandem mass spectrometry method for urinary cortisol and cortisone. Clin Chem 48:1511-1519
23. Rouits E, Boisdron-Celle M, Morel A, Gamelin E (2003) Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6β-hydroxycortisol in routine practice For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake. J Chromatogr B793:357-366
24. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P (1989) The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28:373-387
25. Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M, Canal P (1998) Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 26:229-233
26. Pichard-Garcia L, Hyland R, Baulieu J, Fabre J-M, Milton A, Maurel P (2000) Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. Drug Metab Dispos 28:51-57
27. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE (1999) Morning spot and 24 hour urinary 6 beta-hydroxycortisol to cortisol ratios: Intra-individual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 39:487-494
28. Furuta T, Suzuki A, Mori C, Shibasaki H, Yokokawa A, Kasuya Y (2003) Evidence for the validity of cortisol 6β-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans drug metabolism and disposition. J Chromatogr B 31:1283-1287
29. Amirimani B, Walker AH, Weber BL, Rebbeck TR (1999) RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 91:1588-1590
30. Ando Y, Tateishi T, Sekido Y, Yamamoto T, Satoh T, Hasegawa Y, Kobayashi S, Katsumata Y, Shimokata K, Saito H (1999) Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [letter; comment]. J Natl Cancer Inst 91:1587-1590
31. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M (1999) Intel-individual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem Biophys Res Commun 259:201-205
32. Mauro VF (1993) Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 24:195-202